scholarly journals Relationship Between Botulinum Toxin, Spasticity, and Pain: a Survey of Patient Perception

2015 ◽  
Vol 43 (2) ◽  
pp. 311-315 ◽  
Author(s):  
Adil Shaikh ◽  
Chetan P Phadke ◽  
Farooq Ismail ◽  
Chris Boulias
Keyword(s):  
Botulinum Toxin ◽  
Subjective Experience ◽  
Pain Perception ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Poor Correlation ◽  
Rehabilitation Centre ◽  
Cross Sectional

AbstractObjective: To assess the prevalence of pain in adults with spasticity and to assess the association between the subjective experience of pain and spasticity. Design: Cross-sectional study. Setting: outpatient spasticity management clinic of a rehabilitation centre. Patients: Patients with upper motor neuron lesions and spasticity (n=131) were recruited. Methods: We assessed pain intensity and location, relationship between spasticity and pain perception, and perception of pain relief from botulinum toxin type-A (BoNTA) injections. Main outcome measures: Pain perception rated on a 10-point numerical rating scale and pain quality. Results: 65% of the patients with spasticity reported presence of pain and 60% described it as an aching pain. More patients reported pain with movement (34%) compared to rest (21%). There was a statistically poor correlation between the severity of pain and spasticity (r=0.16; p>0.05). Most patients (80%) believed that their pain was related to spasticity and 62% reported that BoNTA injections decreased their pain. Conclusions: The high incidence of pain noted within our sample suggests that physicians may have to consider pain management as part of spasticity treatment. Participants reported that their pain was related to their spasticity, and that it decreased after BoNTA treatment. Further study is needed to explore the relationships between objective measures of spasticity and pain.

scholarly journals A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm

2016 ◽  
Vol 367 ◽  
pp. 56-62 ◽  
Author(s):  
John Fezza ◽  
John Burns ◽  
Julie Woodward ◽  
Daniel Truong ◽  
Thomas Hedges ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Cross Sectional

A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm

2016 ◽  
Vol 22 ◽  
pp. e138 ◽  
Author(s):  
Daniel Truong ◽  
John Fezza ◽  
John Burns ◽  
Julie Woodward ◽  
Thomas Hedges ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Cross Sectional

Optimization of diagnosing and treatment of cervical dystonia

2020 ◽  
Vol 18 (5) ◽  
pp. 110-116
Author(s):  
С. М. М. СЕХВЕЙЛ ◽  
◽  
З. А. ГОНЧАРОВА ◽  
И. М. БЛИНОВ ◽  
◽  
...  
Keyword(s):  
Computed Tomography ◽  
Cervical Spine ◽  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Rating Scale ◽  
Botulinum Toxin Type A ◽  
Pain Syndrome ◽  
Botulinum Toxin Type ◽  
Botulinum Toxin Therapy ◽  
Before And After

The purpose is to optimize diagnostics of cervical dystonia using multispiral computed tomography (MSCT) of the cervical spine to improve the results of botulinum toxin therapy. Material and methods. 27 patients diagnosed with the idiopathic CD (21 females among them) were examined. The age of patients ranged from 25 to 72 years old (the average age was 40 (3,3)). All the patients were scanned with 3D multispiral computed tomography (MSCT) of the cervical spine in order to verify the dystonic muscles and determine the degree of head and neck rotation. MSCT helped to identify the cervical spine deformation, the level of its displacement and the state of dystonic muscles. The Tsui et al. rating scale was used for assessing the severity of CD before and after the treatment. Also the intensity of pain syndrome was assessed according to the visual analogue scale (VAS) before and after the treatment. All the patients had injections of botulinum toxin type A, in the dose 200–300 U. The time period between the injections was 3,5–4 months. Results. The study revealed that women tend to have cervical dystonia more often (77,8%). Late diagnostics of the disease still remains. The duration of the disease lasted from 1 month to 18 years. Before the treatment the pain syndrome intensity amounted to 5,6 (0,8) points, according to VAS, whereas after the treatment it was 1,9 (0,8) points. The 3D MSCT revealed the deformation of the cervical spine. MSCT helped to verify the dystonic muscles (a bigger surface of the dystonic muscle in comparison with the healthy part, a more «round» image of the muscle). MSCT of the cervical spine enabled to verify the form of dystonia (caput, collis or their combination). Conclusions. Late diagnostics of CD remains. Botulinum toxin therapy is a highly effective way of CD treatment. The efficiency of the botulinum toxin therapy in the given category of patients depends on the right choice of target muscles, the verification of the form of CD and adherence to the early treatment principle.

scholarly journals Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics

2017 ◽  
Vol 45 (1) ◽  
pp. 11-22 ◽  
Author(s):  
Olivia Samotus ◽  
Niraj Kumar ◽  
Philippe Rizek ◽  
Mandar Jog
Keyword(s):  
Botulinum Toxin ◽  
Essential Tremor ◽  
Upper Limb ◽  
Rating Scale ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Functional Improvement ◽  
Motion Sensors ◽  
Dosing Patterns

AbstractBackground:There is a significant need for a targeted therapy for essential tremor (ET), as medications have not been developed specifically for ET, and the ones prescribed are often not well-tolerated, so that many patients remain untreated. Recent work has shown that, unlike previous experience, kinematically guided individualized botulinum toxin type A (BoNT-A) injections provide benefit along with minimal weakness. Ours is the first long-term (96-week) safety and efficacy study of BoNT-A as monotherapy for ET using kinematically driven injection parameters.Methods:Ten ET patients were administered six serial BoNT-A treatments every 16 weeks and were assessed at 6 weeks following treatment. During each study visit, the Fahn–Tolosa–Marin (FTM) scale, the Unified Parkinson’s Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of the treated limb. Participants performed scripted tasks with motion sensors placed over each arm joint. Dosing patterns were determined using the movement disorder neurologist’s interpretation of muscles contributing to the kinematically analyzed upper limb tremor biomechanics.Results:There was a 33.8% (p<0.05) functional improvement (FTM part C) and a 39.8% (p<0.0005) improvement in QUEST score at week 96 compared to pretreatment scores at week 0. Although there was a 44.6% (p<0.0005) non-dose-dependent reduction in maximal grip strength, only 2 participants complained of mild weakness. Following the fourth serial treatment, mean action tremor score was reduced by 62.9% (p=0.001) in the treated and by 44.4% (p=0.03) in the untreated arm at week 96 compared to week 48.Conclusions:Individualized BoNT-A dosing patterns to each individual’s tremor biomechanics provided an effective monotherapy for ET as function improved without functionally limiting muscle weakness.

scholarly journals Oromandibular dystonia in Yemeni patients with khat chewing: a response to botulinum toxin treatment

2014 ◽  
Vol 6 (2) ◽  
Author(s):  
Hatem S. Shehata ◽  
Mohamed S. El-Tamawy ◽  
Nevin Mohieldin ◽  
Mohammed Edrees ◽  
Saeed Bohlega
Keyword(s):  
Botulinum Toxin ◽  
Rating Scale ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Masticatory Muscles ◽  
Secondary Outcome ◽  
Secondary Outcome Measure ◽  
Oromandibular Dystonia ◽  
Toxin A

Khat-(<em>Catha edulis</em>) related oromandibular dystonia is a difficult-to-treat subset of movement disorders that involve masticatory muscles with diverse and incapacitating manifestations. The aim of this study was to evaluate the efficacy of Botulinum toxin-type A therapy in khat chewer Yemeni patients with oromandibular dystonia. This prospective study included 18 khat-chewers Yemeni patients with refractory oromandibular dystonia, who were subjected to Botulinum toxin-A injection and followed up for 3 months thereafter. Primary efficacy outcome was the global impression scale, and secondary outcome measure was the Unified Dystonia Rating Scale. Patients showed improvement of both efficacy measures, maximum satisfactory responses were detected at the forth week after injection. No major adverse events were detected. Botulinum toxin-A is considered an effective and safe treatment option for refractory oromandibular dystonia in khat-chewers.

scholarly journals Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin Type A Injections

2015 ◽  
Vol 151 (11) ◽  
pp. 1194 ◽  
Author(s):  
Murad Alam ◽  
Amelia Geisler ◽  
Divya Sadhwani ◽  
Amita Goyal ◽  
Emily Poon ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Pain Perception ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Needle Size

scholarly journals From Polyanna syndrome to Eeyore’s Corner? Hope and pain in patients with chronic low back pain

2015 ◽  
Vol 46 (1) ◽  
pp. 96-103
Author(s):  
Ewa Wojtyna ◽  
Łukasz Palt ◽  
Katarzyna Popiołek
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Pain Syndrome ◽  
Cross Sectional Study ◽  
Poor Correlation ◽  
Low Back ◽  
Cross Sectional

Abstract Chronic low back pain affects 50-80% of the population, while its consequences may impair the functioning of patients suffering from it, in many spheres of life . Hope is a factor which may influence coping with pain as well as cognitive reflection of pain experience. The aim of the study has been to check: 1) whether dependencies exist between hope-trait and hope-state and the perception of pain; 2) whether experiencing pain at the time of filling questionnaires matters for the assessment of the level of hope; 3) whether there is interaction between hope, the pain experienced at the moment of investigation, and memory of the intensity of previously experienced pain. 150 patients participated in the study, they all reported aggravation of the chronic low back pain syndrome. The study was a cross-sectional study, based on questionnaires. On the third day of treatment the subjects were given the following questionnaires: Trait Hope Scale, State Hope Scale, and Numerical Rating Scale of Pain to fill. Poor correlation was demonstrated to exist between hope-state and hope-pathways on the one hand, and the intensity of minimum pain level experienced during the first three days of treatment. It has been noted that the presence of pain at the time of filling questionnaires results in reducing the hope-state, but only in those persons, who had experienced severe pain previously. On the other hand, in case of patients who had experienced slight pain previously, the pain present when filling in the questionnaires is conducive to enhanced hope-state. The results of the study confirm the complex character of relations between hope and pain.

scholarly journals Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis

Healthcare ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1538
Author(s):  
Yu-Chi Su ◽  
Yao-Hong Guo ◽  
Chung-Lun Liao ◽  
Yu-Ching Lin
Keyword(s):  
Botulinum Toxin ◽  
Randomized Controlled Trials ◽  
Restless Legs Syndrome ◽  
Rating Scale ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Controlled Trials ◽  
Restless Legs ◽  
Randomized Controlled

Our study aimed to investigate the effectiveness and safety of botulinum toxin type A in patients with restless legs syndrome. We searched electronic databases, including PubMed, Cochrane Library, and Web of Science, up to 12 June 2021, for published articles. We enrolled randomized controlled clinical trials and non-randomized controlled studies involving patients with restless legs syndrome who were treated with botulinum toxin. Quality assessment was performed using the Cochrane risk of bias tool and Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental Studies. As for the results, we included four articles comprising 62 participants, two studies were randomized controlled trials. Improvement in International Restless Legs Syndrome Study Group (IRLSSG) rating scale was observed in three studies. Adverse events were temporary and self-limited. Meta-analyses were performed, including the two randomized controlled trials with 27 participants. Compared with placebo, botulinum toxin injection significantly reduced scores of IRLSSG rating scale (SMD, −0.819, 95% confidence interval [CI], −1.377 to −0.262). A total of 11.8% (95% CI, 0.7–72.4%) of patients reported at least one adverse event. In conclusion, botulinum toxin injection may relieve restless legs syndrome related symptoms. However, decisive conclusions cannot be drawn because of the small number of patients included in our meta-analysis. Large-scale, randomized controlled trials are warranted to discover the optimal dose, safety, and long-term effect of intervention with botulinum toxin type A for patients with restless legs syndrome.

Sign in / Sign up

Export Citation Format

Share Document